Expert: Peripheral CB1 receptor inverse agonist designed to reduce metabolic dysfunction while minimizing CNS penetration to avoid neuropsychiatric side effects seen with earlier generation cannabinoid receptor modulators.

Everyday: Blocks a receptor in the brain that normally stimulates appetite, helping reduce food intake and body weight.

Targets: ["CB1"]

Monlunabant - Obesity - Ph2b - Topline H2 2026

Oral CB1 inverse agonist for obesity. Phase 2a showed 7.1kg weight loss but neuropsychiatric AEs (anxiety, sleep disturbance). Phase 2b ongoing. Acquired via Inversago.